Citation Impact
Citing Papers
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
2018 StandoutScienceNobel
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
2010 Standout
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Mouse models of acute and chronic hepacivirus infection
2017 StandoutScienceNobel
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Leukemia in twins: lessons in natural history
2003
Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity
2004 StandoutNobel
Sculpting conducting nanopore size and shape through de novo protein design
2024 StandoutScienceNobel
Mutational landscape and significance across 12 major cancer types
2013 StandoutNature
Opportunities and challenges in the development of kinase inhibitor therapy for cancer
2003
Inhibition of Bcr–Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells
2002
Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes
2009
Inflammation and metabolic disorders
2006 StandoutNature
A view on drug resistance in cancer
2019 StandoutNature
Oncogenic kinase signalling
2001 StandoutNature
DNA methylation in endometrial cancer
2010
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
2011 StandoutNature
The Stat family in cytokine signaling
2001
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia
2003
The SOCS Box of SOCS-1 Accelerates Ubiquitin-dependent Proteolysis of TEL-JAK2
2001
SOCS-1 and SOCS-3 Block Insulin Signaling by Ubiquitin-mediated Degradation of IRS1 and IRS2
2002
STAT3 Is a Negative Regulator of Granulopoiesis but Is Not Required for G-CSF-Dependent Differentiation
2002
Pharmacology of imatinib (STI571)
2002
Thicker Than Blood
2003
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Genomic organization of human JAK2 and mutation analysis of its JH2-domain in leukemia
1999
Eater, a Transmembrane Protein Mediating Phagocytosis of Bacterial Pathogens in Drosophila
2005 StandoutNobel
The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)
2011
The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: A structural analysis of the binding interactions of Gleevec®, Nexavar®, and BIRB-796
2010
Targeting cancer with small molecule kinase inhibitors
2008 Standout
The Molecular Basis of Leukemia
2004
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
STATs in oncogenesis
2000 Standout
Angiogenesis in life, disease and medicine
2005 StandoutNature
Overcoming T cell exhaustion in infection and cancer
2015
MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP
2003
Hypoxia Rescues Frataxin Loss by Restoring Iron Sulfur Cluster Biogenesis
2019 StandoutNobel
Specific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative Splicing
2011
PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma
2004
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells
2005
Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells
2002
Cancer immunotherapy comes of age
2011 StandoutNature
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
How Chemoproteomics Can Enable Drug Discovery and Development
2012
High-throughput kinase profiling as a platform for drug discovery
2008
Comprehensive analysis of kinase inhibitor selectivity
2011 Standout
The STATs of cancer — new molecular targets come of age
2004 Standout
JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cells
2002
JAK-STAT signaling activated by Abl oncogenes
2000
Clonal evolution in cancer
2012 StandoutNature
Cytokine Signaling in 2002
2002 Standout
CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo
2017 StandoutNobel
Targeting the cancer kinome through polypharmacology
2010
Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice
2000
STAT Signaling in Cancer: Insights into Pathogenesis and Treatment Strategies
2006
Comprehensive Integration of Single-Cell Data
2019 Standout
Refined sgRNA efficacy prediction improves large- and small-scale CRISPR–Cas9 applications
2017 StandoutNobel
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
2005 StandoutNature
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
2005 Standout
Progress in the Discovery of Small-Molecule Inhibitors of Bromodomain–Histone Interactions
2011
An intact NEDD8 pathway is required for Cullin‐dependent ubiquitylation in mammalian cells
2002 StandoutNobel
β-Arrestin2 mediates the initiation and progression of myeloid leukemia
2012 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Assessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug Discovery
2008
Human prostasomes express glycolytic enzymes with capacity for ATP production
2013
Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis
2009
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
2003 Standout
Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice
2007 StandoutNobel
Nonimmunoglobulin target loci of activation-induced cytidine deaminase (AID) share unique features with immunoglobulin genes
2012 StandoutNobel
The Protein Kinase Complement of the Human Genome
2002 StandoutScience
Regulation of Jak2 through the Ubiquitin-Proteasome Pathway Involves Phosphorylation of Jak2 on Y1007 and Interaction with SOCS-1
2002
STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells
2000
Constitutive activation ofStat5aby retrovirus integration in early pre-B lymphomas of SL/Kh strain mice
2002
Chromosome translocations and covert leukemic clones are generated during normal fetal development
2002
STAT Signaling in the Pathogenesis and Treatment of Cancer
1999
Deacetylase Activity Is Required for Recruitment of the Basal Transcription Machinery and Transactivation by STAT5
2003
Single-Molecule Protein Phosphorylation and Dephosphorylation by Nanopore Enzymology
2018
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
2003 StandoutNobel
Fusion of the ets Transcription Factor TEL to Jak2 Results in Constitutive Jak-Stat Signaling
1999
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9
2002
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.
2002
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
The Host Defense of Drosophila melanogaster
2007 StandoutNobel
The Halogen Bond
2016 Standout
GENETICS OF MYELOID LEUKEMIAS
2002
The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo
2001
SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma
2003
Impact of interferon-γ on hematopoiesis
2014
Chemical Glycoproteomics
2016 StandoutNobel
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
2004 Standout
Fusion of the ets Transcription Factor TEL to Jak2 Results in Constitutive Jak-Stat Signaling
1999
Autophagy in Health and Disease: A Double-Edged Sword
2004 StandoutScience
Works of Juerg Schwaller being referenced
Structural Analysis Identifies Imidazo[1,2- b ]Pyridazines as PIM Kinase Inhibitors with In vitro Antileukemic Activity
2007
High-Throughput Kinase Profiling: A More Efficient Approach toward the Discovery of New Kinase Inhibitors
2011
PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers
2010
Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes
1998
The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo
2001
Stat5 Is Essential for the Myelo- and Lymphoproliferative Disease Induced by TEL/JAK2
2000
Downregulation of 14-3-3σ in ovary, prostate and endometrial carcinomas is associated with CpG island methylation
2004
MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome
2016
Programmed death 1 signaling on chronic myeloid leukemia–specific T cells results in T-cell exhaustion and disease progression
2009
Targeting PIM Kinases Impairs Survival of Hematopoietic Cells Transformed by Kinase Inhibitor–Sensitive and Kinase Inhibitor–Resistant Forms of Fms-Like Tyrosine Kinase 3 and BCR/ABL
2006
H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor β gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22)
2001
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases
2007
Socs-1 Inhibits TEL-JAK2-Mediated Transformation of Hematopoietic Cells through Inhibition of JAK2 Kinase Activity and Induction of Proteasome-Mediated Degradation
2001
TEL/PDGFβR Induces Hematologic Malignancies in Mice That Respond to a Specific Tyrosine Kinase Inhibitor
1999
TEL/PDGFβR Induces Hematologic Malignancies in Mice That Respond to a Specific Tyrosine Kinase Inhibitor
1999